BioWorld MedTech

Nov. 7, 2011

NewCo on the Block: CerviLenz offers screening tool for preterm birth risk

CerviLenz (Chagrin Falls, Ohio), a woman's health device company in the Cleveland area, has recently bumped its Series A round of investment up to $8.35 million, thanks to a recent tranche of funding from existing investors. Read More

Report from Europe: Ziehm Imaging reports the opening of French sales office

Spinal USA continues down path of growth with 2 recent approvals

Washington roundup: Industry urges CMS to revisit criteria for pass-through codes

Deals roundup: Siemens to acquire HIE developer MobileMD

Agreements/contracts: Bluewater enters western distribution with SurgLine

MDD's Fast Facts

NASS notebook: Medtronic Spinal launches T2 Altitude at NASS conference

Med-Tech Notes: GE Capital reports $5B in healthcare financing

Financings roundup: Tenet launches tender offer for 9% senior notes due 2015

HIT roundup: Nortec to support health IT in underserved communities

Med-Tech Notes: Study: no link between diabetes and kidney stones

Med-Tech Notes: U of Iowa to use GE 7T MRI for brain research

Product Briefs

People in the News

MDD's Neurology Extra

Today's news in brief

BioWorld

BioWorld briefs for June 12, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 9, 2026

3D rendering of β2-Adrenergic receptor GPCR protein molecule embedded in lipid bilayer membrane.

Skape Bio unlocks GPCR targets with de novo-designed miniproteins

BioWorld

Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...

Pre-disease plasma signature may help redefine lung cancer risk

BioWorld

Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...

New 5-HT2C receptor agonists reported in Hansoh patent

BioWorld Science

Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have disclosed tricyclic compounds acting as 5-HT2C receptor...